April 12, 2024 4:47pm

As I have stated, “What goes up with ceremony, goes down with disdain followed by the opposite effect.” Although, being “greedy when others are fearful” is easier said than done.

The Harvard Apparatus RT (OTCQB: HRGN) Chronicles: Ponzi Scheme or a Madoff look-a-life?

Pre-open Indicators: 1 Positive and 1 Negative Indicators

A 360-degree review of the who, why, when and what happened in the sector as the market and economics surround your portfolio defense.

Never leave an investor uninformed! A trusted source of factual reporting!

Week in Review

The present and future value of RegMed Investors (RMi) NEWS sheds light on the stem, cell and gene therapy sector’s risks to share pricing and the sector’s upside acrobatics and potential downslides.

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence! 

 

Friday: The Dow closed DOWN -475.84 points or -1.24%, the S&P closed DOWN -75.65 points or -1.46% while the Nasdaq closed DOWN -267.10 points or -1.62%

 

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes sold off Friday, marking the Dow and S&P 500′s biggest declines of the year, as inflation and geopolitical worries once again dented investor sentiment.

The CBOE Volatility Index, or VIX, rose to its highest level on Friday since October 2023.

On the week, the Dow is down about -2.7%, which would be its largest one-week decline since March 10, 2023. The S&P 500 was on track for a -1.6% weekly decline, its worst week since Oct. 27 and the Nasdaq was down just 0.5%.

Year-ahead inflation expectations rose to 3.1% from 2.9%. Long-run expectations also ticked up to 3% from 2.8%.

Economic Data Docket: The consumer sentiment index for April came in at 77.9, below the Dow Jones consensus estimate of 77.9, according to the University of Michigan’s Surveys of Consumers. Year-ahead and long-run inflation expectations also ticked up, reflecting frustrations over sticky inflation.

 

Friday’s RegMed Investors’ (RMi) opening bell: “don’t. Ramp up buying or selling, there are few candidates I see; “this might be the start of a new run, but it might be a false signal as the indexes, even the Nasdaq, are still in a sideways pattern” <IBD> … https://www.regmedinvestors.com/articles/13415

 

Pre-open Indicators: 1 Positive < CRISPR Therapeutics (CRSP -$2.28)> and 1 Negative Indicators < Solid Biosciences (SLDB -$0.26)>

 

Advance/Decline (A/D) Line:

  • Friday’s advance/decline line at the open was negative with 7 incliner, 25 decliners and 3 flats; ending with a negative close of 3 incliners, 32 decliners and 0 flat
  • Thursday’s advance/decline line at the open was negative with 8 incliner, 24 decliners and 1 flat; ending with a negative close of 14 incliners, 19 decliners and 2 flats
  • Wednesday’s advance/decline line at the open was negative with 3 incliner, 31 decliners and 1 flat; ending with a negative close of 5 incliners, 28 decliners and 2 flats
  • Tuesday’s advance/decline line at the open was positive with 23 incliner, 11 decliners and 1 flat; ending with a positive close of 20 incliners,12 decliners and 3 flats
  • Monday’s advance/decline line at the open was negative with 8 incliner, 26 decliners and 1 flat; ending with a positive close of 23 incliners, 12 decliners and 0 flat

 

Ebb and flow of MY covered sector cell and gene therapy session daily “endings”:

Q2/24: 8 negative and 2 positive closes

Q1/24:

  • March, 1 holiday, 8 positive and 12 negative closes
  • February, 1 holiday, 9 negative and 11 positive closes
  • January: 2 holiday, 12 negative and 8 positive closes

 

Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Friday, the IBB was down -2.08% and the XBI was down -3.43%
  • Thursday, the IBB was up +0.36% and the XBI was up +1.51%
  • Wednesday, the IBB was down -1.80% and the XBI was down -1.84%
  • Tuesday, the IBB was up +1.21% and the XBI was up +1.37%
  • Monday, the IBB was up +0.24% and the XBI was up +0.24%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Friday was up +2.40 points or +16.11% at 17.31
  • Thursday was down -0.88 point or -5.57% at 14.92
  • Wednesday was up +0.84 point or +5.61% at 15.82
  • Tuesday was down -0.21 point or -1.32% at 14.99
  • Monday was down -0.84 point or -5.24% at 15.19

 

Friday’s Closing Down (10 of 32):

  • Blueprint Medicine (BPMC -$5.42 after Thursday’s +$1.76, Wednesday’s -$1.71, Tuesday’s +$0.66 and Monday’s -$0.11),
  • Ultragenyx Pharmaceuticals (RARE -$3.70 after Thursday’s -$0.91, Wednesday’s +$1.05 and Tuesday’s +$0.59),
  • Alnylam Pharmaceuticals (ALNY -$3.59 after Thursday’s -$0.32, Wednesday’s -$3.49, Tuesday’s -$0.14 and Monday’s +$2.48),
  • CRISPR Therapeutics (CRSP -$2.24 after Thursday’s +$1.17, Wednesday’s -$3.45, Tuesday’s +$1.10 and Monday’s +$1.19),
  • Beam Therapeutics (BEAM -$1.34 after Thursday’s +$0.21, Wednesday’s -$2.26, Tuesday’s +$0.51 and Monday’s +$0.61),
  • Sage Therapeutics (SAGE -$1.13 after Thursday’s +$0.12),
  • Regenxbio (RGNX -$0.93 after Thursday’s +$0.17),
  • Vericel (VCEL -$0.82 after Thursday’s -$0.46 after Wednesday’s -$1.16),
  • Ionis Pharmaceuticals (IONS -$0.76 after Thursday’s -$0.44, Wednesday’s +$0.11. Tuesday’s +$0.59 and Monday’s -$0.98),
  • Intellia Therapeutics (NTLA -$0.74 after Thursday’s +$0.06, Wednesday’s -$1.13, Tuesday’s +$0.78 and Monday’s +$0.52),

Friday’s Closing Up (3 of 3):

  • Compass Therapeutics (CMPX +$0.02),
  • Homology Medicine (FIXX +$0.0071),
  • Brainstorm Cell Therapeutics (BCLI +$0.0069),

 

Q2/24 – April

  • Friday closed negative with 3 incliners, 32 decliners and 0 flat
  • Thursday closed negative with 14 incliners, 19 decliners and 2 flats
  • Wednesday closed negative with 5 incliners, 28 decliners and 2 flats
  • Tuesday closed positive with 20 incliners, 12 decliners and 3 flats
  • (4/8) Monday closed positive with 23 incliners, 12 decliners and 0 flat

 

The BOTTOM LINE: Worst week of the year on Friday, after bank earnings were mixed failing to impress and worries increased over escalating conflict in the Middle East.

  • Reiterating, sellers i.e., algorithms and electronic trading) are still in charge …
  • The cell and gene therapy sector tumbled again on Friday after inflation data burned-up hopes the Fed would enter its monetary policy easing phase soon.

 

Last week, I wrote that I favor … caution over the next few weeks! Wednesday … proved me true, yet again!

 

An on-target quote, “inflation is clearly on a different track than the Federal Reserve had planned for after the data this week. In a higher-for-longer environment, he said investors should continue being short on the U.S. 10-year Treasury. Despite the sell-off, financial conditions remain easy. We believe inflation progress will require tighter financial conditions, which should entail still higher long-term rates.” < Barclays analyst Anshul Pradhan>

 

The top three (3) performing in the session:

  • Friday: Compass Therapeutics (CMPX), Brainstorm Cell Therapeutics (BCLLI) and Homology Medicine (FIXX)
  • Thursday: Blueprint Medicine (BPMC), CRISPR Therapeutics (CRSP) and Generation Bio (GBIO)
  • Wednesday: Ultragenyx Pharmaceuticals (RARE), Harvard Apparatus RT (OTCQB: HRGN) and Compass Therapeutics (CMPX)
  • Tuesday: CRISPR Therapeutics (CRSP), BioLife Solutions (BLFS) and Intellia Therapeutics (NTLA)
  • Monday: Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP) and Beam Therapeutics (BEAM)

The worst three (3) in the session:  

  • Friday: Blueprint Medicine (BPMC), Ultragenyx Pharmaceuticals (RARE) and Alnylam Pharmaceuticals (ALNY)
  • Thursday: Ultragenyx Pharmaceuticals (RARE), Vericel (VCEL) and Ionis Pharmaceuticals (IONS),
  • Wednesday: CRISPR Therapeutics (CRSP), Alnylam Pharmaceuticals (ALNY) and Blueprint Medicine (BPMC)
  • Tuesday: Adverum Biotechnologies (ADVM), Mesoblast (MESO) and Generation Bio (GBIO)
  • Monday: Ionis Pharmaceuticals (IONS), Vericel (VCEL) and Voyager Therapeutics (VYGR)

 

BEWARE… How MANY TIMES AM I RIGHT … MORE than MOST!!

The Harvard Apparatus RT (OTC QB HRGN) Chronicles: shows how the “pimp/pump and promote” share pricing works with WHAT news for so long …my treatise is VALIDATED!

Yet a further SCREW-JOB for early and present investors ...

  • Friday closed down -$0.33 (was -$0.85 with 1400 shares traded) with 1,649 shares traded
  • Thursday closed flat with 25 shares traded
  • Wednesday closed up +$0.09 with 900 shares traded
  • Tuesday closed flat with 0 shares traded
  • (4/8) Monday closed up +$0.48 with 4,715 shares traded
  • Friday closed flat with 800 shares traded
  • Thursday closed down -$0.68 with 13,300 shares traded
  • Wednesday closed down -$0.002 with 800 shares traded
  • Tuesday closed $0.00 with 11,900 shares traded
  • (4/1) Monday was up +$0.05 with 1,926 shares traded

Question, has major shareholder and landlord, Harvard Bioscience (HBIO) in the midst of a lay-off; have been left holding a depreciating “bag” of shares (5% or 697,112 shares – SC 13G/A filing) from its $4 M share of the wrongful death lawsuit settlement having been issued 4,000 shares of series E 8% convertible Preferred stock at a price of $1,000 per share to satisfy the indemnification obligations (10-K)? 

  • How will HBIO protect itself and its asset/balance sheet when and who will NOT finance this OTCQB: HRGN pig with this its lipstick and lingering odor?

Did you notice how it barely trades unless volume is being “pumped.”  This question needs to be answered as HRGN is desperate to finance by any means as past Chinese private placement investors must be feeling … WHAT … TAKEN to the cleaners?

Question, Is it a Ponzi Scheme?

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.